JP2024545428A5 - - Google Patents
Info
- Publication number
- JP2024545428A5 JP2024545428A5 JP2024532763A JP2024532763A JP2024545428A5 JP 2024545428 A5 JP2024545428 A5 JP 2024545428A5 JP 2024532763 A JP2024532763 A JP 2024532763A JP 2024532763 A JP2024532763 A JP 2024532763A JP 2024545428 A5 JP2024545428 A5 JP 2024545428A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- adc
- cancer
- drug conjugate
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306692.1 | 2021-12-02 | ||
| EP21306692 | 2021-12-02 | ||
| US202263385375P | 2022-11-29 | 2022-11-29 | |
| US63/385,375 | 2022-11-29 | ||
| PCT/EP2022/084107 WO2023099683A1 (en) | 2021-12-02 | 2022-12-01 | Cea assay for patient selection in cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545428A JP2024545428A (ja) | 2024-12-06 |
| JP2024545428A5 true JP2024545428A5 (https=) | 2025-12-09 |
Family
ID=84688277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024532763A Pending JP2024545428A (ja) | 2021-12-02 | 2022-12-01 | 癌治療における患者選択のためのｃｅａアッセイ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041434A1 (https=) |
| EP (1) | EP4440603A1 (https=) |
| JP (1) | JP2024545428A (https=) |
| KR (1) | KR20240112348A (https=) |
| AU (1) | AU2022400237A1 (https=) |
| CA (1) | CA3239856A1 (https=) |
| IL (1) | IL313224A (https=) |
| MX (1) | MX2024006766A (https=) |
| TW (1) | TW202339804A (https=) |
| WO (1) | WO2023099683A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3199552T3 (da) * | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| AU2021379882A1 (en) | 2020-11-10 | 2023-06-29 | Sanofi | Ceacam5 antibody-drug conjugate formulation |
| EP4427763A1 (en) * | 2023-03-06 | 2024-09-11 | Sanofi | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies |
| KR20250169564A (ko) * | 2023-03-23 | 2025-12-03 | 사노피 | 암 치료법에서 환자 선택을 위한 CEACAM5 mRNA 검정 |
| WO2025169012A1 (en) | 2024-02-06 | 2025-08-14 | Sanofi | Methods of treating ceacam5-expressing cancers |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| US20090226444A1 (en) * | 2005-12-21 | 2009-09-10 | Micromet Ag | Pharmaceutical antibody compositions with resistance to soluble cea |
| MX2009000709A (es) | 2006-07-18 | 2009-02-04 | Sanofi Aventis | Anticuerpo antagonista contra epha2 para el tratamiento de cancer. |
| DK3199552T3 (da) | 2012-11-20 | 2020-03-30 | Sanofi Sa | Anti-ceacam5-antistoffer og anvendelser heraf |
| CN107753954A (zh) * | 2012-12-13 | 2018-03-06 | 免疫医疗公司 | 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量 |
| CA2924398A1 (en) * | 2013-11-05 | 2015-05-14 | Immunomedics, Inc. | Humanized anti-ceacam5 antibody and uses thereof |
| AU2016274989A1 (en) * | 2015-06-12 | 2017-11-02 | Immunomedics, Inc. | Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs |
-
2022
- 2022-12-01 EP EP22830697.3A patent/EP4440603A1/en active Pending
- 2022-12-01 WO PCT/EP2022/084107 patent/WO2023099683A1/en not_active Ceased
- 2022-12-01 IL IL313224A patent/IL313224A/en unknown
- 2022-12-01 MX MX2024006766A patent/MX2024006766A/es unknown
- 2022-12-01 TW TW111146177A patent/TW202339804A/zh unknown
- 2022-12-01 CA CA3239856A patent/CA3239856A1/en active Pending
- 2022-12-01 KR KR1020247021675A patent/KR20240112348A/ko active Pending
- 2022-12-01 AU AU2022400237A patent/AU2022400237A1/en active Pending
- 2022-12-01 JP JP2024532763A patent/JP2024545428A/ja active Pending
- 2022-12-01 US US18/715,666 patent/US20250041434A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024545428A5 (https=) | ||
| US12497465B2 (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| KR102905497B1 (ko) | 항체-약물 컨쥬게이트와 parp 저해제의 조합 | |
| AU2016202621B2 (en) | Combination of inotuzumab ozogamicin and torisel for the treatment of cancer | |
| JP2022523155A5 (https=) | ||
| JP2024545427A5 (https=) | ||
| JP2026021442A (ja) | 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療 | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2024542095A5 (https=) | ||
| CN114302745A (zh) | 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法 | |
| TW202116353A (zh) | 使用酞菁染料靶向分子結合物之治療方法 | |
| RU2024118193A (ru) | Анализ на рэа отбора пациентов для противоопухолевой терапии | |
| CA3122946C (en) | Combination of antibody-drug conjugate with parp inhibitor | |
| EA050611B1 (ru) | Комбинация конъюгата антитела-лекарственного средства и ингибитора тубулина | |
| HK40043732A (en) | Combination of antibody-drug conjugate and tubulin inhibitor | |
| RU2024118187A (ru) | Комбинированная терапия, предусматривающая ceacam5-направленный adc с антителом к pd1/pd-l1 | |
| JP2025540063A (ja) | 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用 | |
| WO2026021442A1 (zh) | 抗体药物偶联物在制备治疗肺癌的药物中的用途 | |
| WO2025190318A1 (zh) | 抗her2抗体药物偶联物和her二聚化抑制剂联合治疗实体瘤 | |
| CA3287886A1 (en) | Combination of anti-cdh6 antibody-drug conjugate and hif-2a inhibitor | |
| RU2025128785A (ru) | АНАЛИЗ mRNA CEACAM5 ДЛЯ ОТБОРА ПАЦИЕНТОВ В ТЕРАПИИ РАКА | |
| HK40064358A (en) | Combination of antibody-drug conjugate with parp inhibitor | |
| RU2025126657A (ru) | Применение иммуноконъюгатов, связывающих ceacam5, для лечения видов нейроэндокринного рака, экспрессирующих ceacam5 | |
| RU2021125713A (ru) | Применение иммуноконъюгатов к ceacam5 для лечения рака легкого | |
| BR122024023393A2 (pt) | Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica |